The Significance of Angiogenesis Processes and Their Target Biomarkers in Ovarian Cancer: Clinical and Prognostic Analysis
Keywords:
Ovarian cancer, immunohistochemistry, p53Abstract
This article analyzes the expression of immunohistochemical markers (p53, Ki-67, VEGF, and CD34) in various histological types of ovarian cancer, along with their clinical-morphological features and prognostic significance. Marker expression levels were evaluated in relation to tumor progression, treatment effectiveness, and recurrence risk. The obtained results provide a scientific foundation for formulating individualized therapeutic strategies.
References
Prat J. A synopsis of the 2014 WHO classification of tumors of the female reproductive organs. Mod Pathol. 2015.
Bell D. et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011.
McCluggage WG. Morphological subtypes of ovarian carcinoma. Histopathology. 2011.
Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer. Am J Surg Pathol. 2010.
Köbel M. et al. Differences in tumor biology between histological subtypes of ovarian cancer. Int J Gynecol Pathol. 2014.
Yemelyanova A. et al. Immunohistochemical p53 staining in ovarian cancer. Mod Pathol. 2011.
Cannistra SA. Cancer of the ovary. N Engl J Med. 2004.
Ferrara N. VEGF: basic science and clinical progress. Endocr Rev. 2004.
Hlatky L, Hahnfeldt P. Clinical implications of angiogenesis in cancer. N Engl J Med. 1996.
American Cancer Society. Ovarian Cancer Statistics. 2023.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nigora Zaripovna Babajanova, Yashnar Salievna Mamadaliyeva
This work is licensed under a Creative Commons Attribution 4.0 International License.
